Cross-talk between estrogen receptors and insulin-like growth factor-I receptor in the brain: Cellular and molecular mechanisms

2006 ◽  
Vol 27 (4) ◽  
pp. 391-403 ◽  
Author(s):  
Pablo Mendez ◽  
Francisco Wandosell ◽  
Luis M. Garcia-Segura
2002 ◽  
Vol 83 (1-5) ◽  
pp. 211-217 ◽  
Author(s):  
Gloria Patricia Cardona-Gómez ◽  
Pablo Mendez ◽  
Lydia L. DonCarlos ◽  
Iñigo Azcoitia ◽  
Luis M. Garcia-Segura

2001 ◽  
Vol 37 (1-3) ◽  
pp. 320-334 ◽  
Author(s):  
Gloria Patricia Cardona-Gómez ◽  
Pablo Mendez ◽  
Lydia L DonCarlos ◽  
Iñigo Azcoitia ◽  
Luis M Garcia-Segura

2009 ◽  
Vol 111 (1) ◽  
pp. 164-170 ◽  
Author(s):  
Lauren Fletcher ◽  
Sanjivan Kohli ◽  
Shane M. Sprague ◽  
Robert A. Scranton ◽  
Stuart A. Lipton ◽  
...  

Object Individually, the cytokines erythropoietin (EPO) and insulin-like growth factor–I (IGF-I) have both been shown to reduce neuronal damage significantly in rodent models of cerebral ischemia. The authors have previously shown that EPO and IGF-I, when administered together, provide acute and prolonged neuroprotection in cerebrocortical cultures against N-methyl-d-aspartate–induced apoptosis. The aim of this study was to determine whether intranasally applied EPO plus IGF-I can provide acute neuroprotection in an animal stroke model and to show that intranasal administration is more efficient at delivering EPO plus IGF-I to the brain when compared with intravenous, subcutaneous, or intraperitoneal administration. Methods The EPO and IGF-I were administered intranasally to mice that underwent transient middle cerebral artery occlusion (MCAO). Stroke volumes were measured after 1 hour of MCAO and 24 hours of reperfusion. To evaluate the long-term effects of this treatment, behavioral outcomes were assessed at 3, 30, 60, and 90 days following MCAO. Radiography and liquid scintillation were used to visualize and quantify the uptake of radiolabeled 125I-EPO and 125I–IGF-I into the mouse brain after intranasal, intravenous, subcutaneous, or intraperitoneal administration. Results Intranasal administration of EPO plus IGF-I reduced stroke volumes within 24 hours and improved neurological function in mice up to 90 days after MCAO. The 125I-EPO and 125I–IGF-I were found in the brain within 20 minutes after intranasal administration and accumulated within the injured areas of the brain. In addition, intranasal administration delivered significantly higher levels of the applied 125I-EPO and 125I–IGF-I to the brain compared with intravenous, subcutaneous, or intraperitoneal administration. Conclusions The data demonstrate that intranasal EPO plus IGF-I penetrates into the brain more efficiently than other drug delivery methods and could potentially provide a fast and efficient treatment to prevent chronic effects of stroke.


2000 ◽  
Vol 20 (8) ◽  
pp. 2926-2933 ◽  
Author(s):  
Eva Carro ◽  
Angel Nuñez ◽  
Svetlana Busiguina ◽  
Ignacio Torres-Aleman

Sign in / Sign up

Export Citation Format

Share Document